Customize this page|
2
Votes
vote
Kylin Therapeutics receives notice of allowance for its first U.S. patent applicationOfficials of Kylin Therapeutics Inc., a leading RNAi company, announced that they have received a notice of allowance from the U.S. Patent and Trademark Office for its first U.S. patent application. ... |
|
2
Votes
vote
AVI BioPharma receives $11.5M DTRA fund to develop AVI-7012 for treating Junin virus infectionAVI BioPharma, Inc. a developer of RNA-based drugs, announced today that it has received expanded contract funding of approximately $11.5 million from the Defense Threat Reduction Agency's (DTRA) Transformational Medical Technologies Initiative (TMTI) to support development of the Investigational... |
|
0
Votes
vote
Array BioPharma to present poster on ARRY-403 glucokinase activatorArray BioPharma Inc. today announced that a poster on ARRY-403, a novel, oral, glucokinase activator (GKA), will be presented at the European Association for the Study of Diabetes annual meeting, on October 2, 2009, in Vienna, Austria. ... |
|
2
Votes
vote
DOR Biopharma to raise $3.85 million from institutional investorsDOR BioPharma, Inc. (DOR or the Company) (OTC Bulletin Board: DORB), a late-stage biotechnology company, announced today that it has entered into common stock purchase agreements with institutional investors totaling approximately $3.85 million. DOR's North American commercial partner, Sigma-Tau ... |
|
0
Votes
vote
Ondine Biopharma Raises $618,000 from Partial Sale of Grafton InvestmentVANCOUVER, BRITISH COLUMBIA--(Marketwire - Sept. 23, 2009) - Ondine Biopharma Corporation (the "Company" or "Ondine") (TSX:OBP)(AIM:OBP), a medical device company developing photodisinfection based products, today announced it has received cash proceeds of $618,000 (US$577,500... |
|
0
Votes
vote
AVI BioPharma, Inc. Announces Presentations at Upcoming Investment ConferencesBOTHELL, WA--(Marketwire - September 15, 2009) - AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced that management will participate in the following upcoming investment conferences in New York. UBS Global Investment Conference Tuesday, Sept. 22, 2009 1 p.m. ET... |
